Commensurate with the tumour-suppressor capabilities of TRPV1, the expression of TRPV1 has been shown to be significantly decreased in the high-grade glioma, glioblastoma multiforme (GBM), thereby potentially reducing the therapeutic benefits of CBD in advanced patients [75]. This evidence concerns the gene TRPV1 and central nervous system cancer.